Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5536351 | Vaccine | 2017 | 8 Pages |
Abstract
Future research and innovation will beneficially inform Canadian jurisdictions when considering whether to administer the nonavalent vaccine, whether to implement a two or one-dose vaccination schedule, and how to improve uptake and rates of completion. The usefulness of standardizing methodologies for collecting and reporting HPV vaccination coverage and implementing a national registry were identified as important priorities.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Gilla K. Shapiro, Juliet Guichon, Margaret Kelaher,